key: cord-0948171-h9hugan3
authors: Stadler, Konrad; Roberts, Anjeanette; Becker, Stephan; Vogel, Leatrice; Eickmann, Markus; Kolesnikova, Larissa; Klenk, Hans-Dieter; Murphy, Brian; Rappuoli, Rino; Abrignani, Sergio; Subbarao, Kanta
title: SARS Vaccine Protective in Mice
date: 2005-08-03
journal: Emerg Infect Dis
DOI: 10.3201/eid1108.041003
sha: 9e04e344099e9f7ae40628aba46e4a2cf65aa876
doc_id: 948171
cord_uid: h9hugan3

nan

To the Editor: Less than a year after the identification of the severe acute respiratory syndrome coronavirus (SARS-CoV) (1), 3 independent laboratories reported protection from SARS-CoV challenge in animal models using a DNA vaccine or recombinant forms of the modified vaccinia Ankara or a parainfluenza virus, encoding the spike gene (2) (3) (4) . Their protective efficacies are encouraging because they provide proof that a SARS-CoV vaccine is feasible. However, vaccines based on those technologies are not licensed for human use, and recommendation and licensing will likely take many years. We have developed an inactivated virus vaccine that induces neutralizing antibodies and protects against SARS-CoV challenge.

The vaccine was produced as described elsewhere (5) . Briefly, the SARS-CoV (strain FRA, GenBank accession no. AY310120) was grown in Vero cells, inactivated with β-propiolactone (BPL), and complete inactivation was confirmed by 2 consecutive passages on Vero cells. Inactivated virus was purified by column chromatography followed by sucrose gradient centrifugation. The fraction containing virus was dialyzed against phosphate-buffered saline pH 7.2, and total protein content was determined by using the Micro BCA Protein Assay Kit (Pierce Biotechnology, Rockford, IL, USA). Immunogenicity of the vaccine was tested by immunizing BALB/c mice at 0, 2, and 4 weeks with 5 µg of inactivated virus combined with the adjuvant MF59, an oil squalene-in-water emulsion (6) approved for human use in Europe for an influenza vaccine. Ten days after the third immunization, serum samples were tested for the presence of SARS-CoV spike protein-specific antibodies by using enzyme-linked immunosorbent assay, and high titers (1-3 × 10 4 ) of anti-SARS-CoV spike immunoglobulin (Ig) G antibodies were detected. IgG subclass determination indicated a predominant Th2-type immune response similar to that observed in BALB/c mice vaccinated with a UVinactivated SARS-CoV plus alum (7) .

Efficacy of the inactivated virus vaccine was also assessed in a BALB/c mouse model of SARS-CoV infection (8) . Animal studies were approved by the National Institutes of Health Animal Care and Use Committee and were conducted in an animal biosafety level 3 facility. SARS-CoV replicates in the respira-tory tract of BALB/c mice following intranasal infection with 10 4 50% tissue culture infectious doses (TCID 50 ) of virus. Generally, virus titers peak within 2 days after infection and are cleared within 7 days (8) . BALB/c mice were immunized at 0, 2, and 4 weeks with 5 µg of BPL-inactivated SARS virus with or without the MF59 adjuvant. Mice were also immunized with 4 different control preparations: phosphate-buffered saline, adjuvant MF59 alone, and 5 µg of BPL inactivated influenza A virus vaccine with or without MF59. Serum samples were collected 2 weeks after each dose, and assayed for their ability to neutralize SARS-CoV (8) . After 2 vaccine doses, SARS-CoV neutralizing antibodies were detected only in the group of mice immunized with the BPL-inactivated SARS virus vaccine plus MF59 adjuvant (1:91). Two weeks after the third dose, the BPLinactivated SARS virus vaccine without MF59 induced neutralizing titers of 1:64, while the adjuvanted vaccine elicited neutralizing titers >1:600 (Table) .

Mice were challenged intranasally at this point with 10 4 TCID 50 SARS-CoV (Urbani strain, GenBank accession no. AY278741). Nasal turbinates and lung tissues were analyzed for infectious virus 2 days later (Table) . SARS-CoV titers in mice from the control groups were ≈10 6 TCID 50 virus/g of lung tissue and ≈10 3 TCID 50 virus/g of nasal turbinate tissue. Complete protection from virus replication was observed in mice that received the MF59 adjuvanted SARS-CoV vaccine. Immunization with the nonadjuvanted vaccine resulted in complete protection of the upper respiratory tract and a significant reduction (30,000-fold) of viral titers in the lower respiratory tract compared to the control groups. The incomplete protection of this group was attributed to a single animal that contained detectable infectious virus in the lung. Accelerated or enhanced virus replication or disease in immunized persons is a concern in developing any vaccine. This may be particularly true for SARS-CoV vaccines since adverse effects have been reported for one animal coronavirus vaccine, feline infectious peritonitis virus (9) . Additionally, some in vitro experiments were performed with pseudotyped lentiviruses that expressed the spike glycoprotein derived from SARS-like virus isolated from civets. In these experiments, the presence of antibodies that neutralized most human isolates of SARS-CoV demonstrated enhanced entry into renal epithelial cells (10) . In our studies, we did not find enhanced virus replication in the respiratory tract of vaccinated mice upon SARS-CoV challenge. However, since mice are a model of SARS-CoV infection but not disease, the issue of disease enhancement will have to be carefully evaluated if and when an appropriate animal model in which this phenomenon can be demonstrated becomes available.

In summary, an inactivated SARS-CoV vaccine, produced with a technology that has a safety record established by immunizing hundreds of millions of persons, protects mice from challenge with SARS-CoV. The vaccine adjuvanted with MF59 elicits neutralizing antibodies (titer 1:91) after only 2 doses. We conclude that the vaccine described here has desirable properties, and our data support further development and plans for clinical trials.

A novel coronavirus associated with severe acute respiratory syndrome

DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice

Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice

Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS

Synthesis and characterization of a native, oligomeric form of recombinant severe acute respiratory syndrome coronavirus spike glycoprotein

MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile

A subcutaneously injected UV-inactivated SARS coronavirus vaccine elicits systemic humoral immunity in mice

Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice

Early death after feline infectious peritonitis virus challenge due to recombinant vaccinia virus immunization

Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses

Addresses for correspondence: Sergio Abrignani, Chiron Vaccines, Via Fiorentina 1

To the Editor: Ningxia is the smallest provincial autonomous region on the Loess Plateau in central China, with a population of ≈5.5 million persons composed of 35 ethnic and various religious groups. The natural environmental conditions and socioreligious ethnic status in Ningxia, particularly the southern region, are conducive to sheep farming, an important part of the agricultural economy. Both cystic echinococcosis (CE) and alveolar echinococcosis (AE) (1) are endemic in the northwest part of China; high prevalences have been reported in several provinces (1), including Gansu (2,3) and the Xinjiang Uigur Autonomous Region (4). Little information is available about the extent of human echinococcosis in Ningxia; this is the first report of a provincial investigation for both human CE and AE there.We conducted a retrospective survey of clinical records from 7 local county hospitals and 4 other hospitals in Yinchuan to determine the epidemiology of human echinococcosis in southern Ningxia. All surgical and clinical records were checked, and diagnoses were confirmed based on imaging, surgical reports, and histopathologic reports. Data concerning age, sex, domicile, ethnicity, occupation, year of diagnosis, cyst or lesion numbers and anatomical location, type and duration of anthelminthic treatment (if given), and the nature and number of surgeries performed for echinococcosis were recorded for each confirmed CE and AE patient.From 1985 to 2002, a total of 2,216 cases of echinococcosis were recorded, most of which were due to CE (96%). The incidence of combined CE and AE from 1994 to 2001 was 7/100,000 persons for southern Ningxia, compared with 1/100,000 persons for Yinchuan in the north